Natera, Inc. ($NTRA) Stock Forecast: Up 5.1% Today

What is Natera, Inc.?

Natera, Inc. (NTRA) recently obtained FDA approval for its Signatera CDx blood test, marking a significant advancement in personalized oncology care for the healthcare diagnostics company. The company currently faces a combination of clinical successes and financial difficulties.

Why is Natera, Inc. going up?

NTRA stock is up 5.1% on May 20, 2026 14:21

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA)

Natera, Inc. (NTRA) recently received FDA approval for its Signatera CDx blood test, marking it as the first blood-based minimal residual disease companion diagnostic for guiding immunotherapy decisions in muscle-invasive bladder cancer. This approval validates MRD testing as a clinical decision tool and could strengthen Natera's oncology narrative, driving increased revenue expectations. However, investors should also consider the company's continued high spending, leading to ongoing losses, and growing legal/regulatory pressures despite the clinical win.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/fda-nod-for-signatera-mrd-blood-test-might-change-the-case-f

NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer

Natera, Inc. (NTRA) announced that its Signatera CDx received FDA approval as a companion diagnostic for adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer (MIBC). This marks the first companion diagnostic approval in blood-based minimal residual disease (MRD) testing and is expected to significantly advance personalized oncology care. The approval is supported by positive findings from the Phase III IMvigor011 trial, which demonstrated improved outcomes for MRD-positive patients and the potential for personalized treatment decisions for MRD-negative patients.

https://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/1997032/ntras-signatera-cdx-wins-fda-nod-in-muscle-invasive-bladder-cancer/

Natera wins FDA approval for companion diagnostic

Natera has secured FDA approval for its blood-based molecular residual disease test, Signatera CDx, as a companion diagnostic. This test will help physicians identify muscle-invasive bladder cancer patients post-surgery who would benefit from Genentech’s immunotherapy Tecentriq, and conversely, those who may avoid unnecessary treatment. The approval highlights the growing role of MRD testing in guiding personalized cancer treatment and potentially reducing healthcare costs.

https://www.medtechdive.com/news/natera-wins-fda-approval-for-companion-diagnostic/820450/

A Look At Natera (NTRA) Valuation After Recent Share Price Weakness

Natera (NTRA) has seen recent share price weakness, with a 10.6% drop over the past month, despite strong multi-year total returns and 14.8% revenue growth. The stock is currently trading at a roughly 39% discount to an intrinsic estimate of $259.11, suggesting it may be undervalued. This valuation is based on assumptions of ambitious growth, profitability improvements through new product launches, and personalized medicine trends, while acknowledging risks like clinical trial setbacks and high R&D costs.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/a-look-at-natera-ntra-valuation-after-recent-share-price-wea-1

Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings

Natera, Inc. (NTRA), a key player in healthcare diagnostics with a $26.69 billion market cap, shows strong long-term growth prospects despite current losses. Analysts project a potential upside of nearly 40% with an average target price of $260.89, supported by impressive revenue growth of 38.80% and overwhelmingly positive analyst sentiment. The company, known for its innovative molecular testing services, is heavily investing in future growth with 17 buy ratings and no sell ratings.

https://www.directorstalkinterviews.com/natera-inc-ntra-investor-outlook-exploring-a-39-99-upside-with-strong-buy-ratings/4121251799

Trending Today

Crude Oil ($CRUDE) Commodity Forecast: Down 5.1% Today

Brent Crude Oil ($BRENT) Commodity Forecast: Down 5.1% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.3% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Up 5.5% Today

D.R. Horton Inc. ($DHI) Stock Forecast: Up 5.1% Today

Micron Technology Inc. ($MU) Stock Forecast: Up 5.5% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Up 5.9% Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 7.5% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 5.0% Today

Etsy Inc. ($ETSY) Stock Forecast: Up 5.9% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

20.04.2026 - NTRA Stock was up 5.1%

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

14.03.2026 - NTRA Stock was up 5.8%

• Today's positive performance by Natera is linked to William Blair's initiation of coverage on the company, endorsing its strong position in diagnostic markets and growth potential.
• The encouraging interim futility analysis from Allogene Therapeutics' MRD-Guided ALPHA3 Trial, which uses Natera's CLARITY™ MRD assay, also contributed to the optimistic outlook by demonstrating successful MRD clearance in high-risk patients.
• Furthermore, a recent court ruling that mandates a 30% ongoing royalty payment to Natera in a patent dispute is seen as a significant victory for the company, reinforcing its intellectual property rights and hinting at future financial gains.
• Despite concerns such as potential overvaluation and insider sales, Natera's leadership in the market, early-mover advantage, and progress in cancer research are likely bolstering investor confidence in its future growth opportunities.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

16.03.2026 - NTRA Stock was down 6.8%

• The bearish movement in Natera's stock today could be attributed to the mixed evaluations of its share price performance, with conflicting assessments of undervaluation and overvaluation.
• Despite being positioned to capture a significant share of the $20 billion MRD opportunity and receiving an 'Outperform' rating from William Blair, concerns about overvaluation and insider selling may have dampened investor sentiment.
• The positive interim results from Allogene Therapeutics’ ALPHA3 trial, showcasing the effectiveness of cema-cel in reducing MRD levels in lymphoma patients, could have been overshadowed by broader market uncertainties or profit-taking activities.
• Natera's strong growth potential and competitive advantages in the diagnostics sector may still underpin its long-term prospects, despite short-term market fluctuations.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.